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UCB Pharma asked Geoffrey Burnstock to propose a
programme of 8 international leaders in the glia-neuron
interaction and purinergic signalling field to participate in a
meeting aimed at introducing the topic to about 30
members of the Company to consider the therapeutic
potential of purinergic signalling compounds for the
treatment of neurological disorders, including: epilepsy,
neurodegenerative diseases, movement disorders, neuro-
protection, mood disorders and neuropathic pain.
Geoff Burnstock, acting as the Chairman of this 1-day
meeting, held at the Château de Limelette, Belgium,
introduced the objectives of the meeting. He stressed the
sophisticated biology that was involved in drug develop-
ment and the advantages of collaborations between basic
scientists, clinicians and the drug industry in bringing
advances in knowledge from basic science to application in
clinical medicine for the treatment of disease.
The morning session was devoted to the mechanisms
underlying glia-neuron interactions. Professor Philip
Haydon from the Department of Neuroscience, University
of Pennsylvania, USA, led off by describing ‘The tripartite
synapse: how astrocytes listen and talk to neurons’,
describing the functional as well as structural interactions
between three elements: the neuronal presynaptic compo-
nent, the postsynaptic neuronal component and the peri-
synaptic astrocyte.
Astrocytes are intimately associated with neurons and,
through their extensive contacts with synapses, they are
able to regulate synaptic transmission. Since the discovery
of the ability of astrocytes to release chemical transmitters,
a process that is termed gliotransmission, our understanding
of the dynamical regulatory roles for these glial cells has
dramatically expanded. Astrocytes are equipped with the
necessary machinery to listen and to talk to neurons.
Following synaptic activity neurotransmitters acting
through glial metabotropic receptors induce glial Ca
2+
signals. In turn, these Ca
2+ signals can induce the release
of a variety of chemical transmitters, including glutamate,
ATP and D-serine.
Using a variety of astrocyte-specific manipulations
recent work has identified a variety of physiological and
pathological functions for this process of gliotransmission.
By releasing ATP, which is converted in the extracellular
space to adenosine, astrocytes exert a powerful presynaptic
inhibition of synaptic transmission. Glutamate and D-serine
released from astrocytes activate neuronal N-methyl-D-
aspartate (NMDA) receptors. These glial-neuron signalling
pathways regulate neuronal excitability and synaptic trans-
mission. When examined in vivo recent studies show that
neuronal networks are under the continuous modulatory
control of the astrocyte through both purinergic and NMDA
receptor-dependent pathways. In addition to providing
physiological modulatory actions, astrocytes have the
potential to contribute to neurological disorders and
psychiatric states. The contribution of gliotransmission to
delayed neuronal death was discussed.
He concluded that our understanding of brain function is
changing from one in which neuron-based electrical signals
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neuronal networks interact with slow modulatory signals
provided by glia. The ultimate function or dysfunction of the
nervous system during health and disease is an emergent
property of these neuron-glial interactions.
The next lecture was presented by Professor Andrea
Volterra, from the Department of Cell Biology and
Morphology, University of Lausanne, Switzerland. His
talk, entitled ‘Gliotransmission, synaptic plasticity and
synaptic dysfunction’, focused on the process of exocyto-
sis of glutamate and other ‘gliotransmitters’ released from
astrocytes and on modes of rapid communication of
glia with neighbouring cells. Using an interdisciplinary
approach, he described the mechanisms of gliotransmission
in the normal brain physiology and in brain diseases, as
well as identifying signalling steps that may contribute to
novel drug targets. He discussed how glial activity follows
two routes: an intracellular one through gap junctions
(connexins) and an extracellular one via release of ATP,
glutamate and serine. Astrocytes also contain a synaptic-
like microvessel compartment for uptake, storage and
release of glutamate. Such gliotransmission plays a role in
synapse formation, synaptic function, adult neurogenesis
and neurovascular tone.
Astrocytes control excitatory transmission and synaptic
strength at hippocampal synapses via purinergic P2Y1
receptor signalling, glutamate and tumour necrosis factor-
α (TNFα). Modulatory control in the hippocampal dentate
gyrus in response to activation of P2Y1 purinoreceptors
(P2Y1R) was shown and immunochemistry demonstrated
that P2Y1Rs are localised preferentially in astrocyte
processes directly apposed to asymmetric synapses in the
dentate molecular layer. In hippocampal slices, activation of
P2Y1R with the selective agonist, 2-methylthioadenosine-
5′-diphosphate (2-MeSADP), triggers glutamate release.
P2Y1R activation with 2-MeSADP causes increased
miniature excitatory postsynaptic currents (mEPSC) and
spontaneous EPSC (sEPSC) activity in dentate granule cells
(CG). P2Y1R signalling in astrocytes activates presynaptic
NMDA receptors via release of glutamate.
Post-embeddingimmunogoldcytochemistryshowedgold
particles in the extrasynaptic portion of excitatory nerve
terminals.Stimulationofastrocyte P2Y1R induces release of
TNFα in addition to glutamate. The two signalling events
are correlated, as P2Y1R-evoked glutamate release is
dramatically reduced in TNFα knockout mice.
Professor Christian Steinhäuser, Director of the
Institute of Cellular Neuroscience, University of Bonn,
Germany, gave a talk entitled ‘A role for astrocytes in
epilepsy’. He suggested that astrocytes may be active
players in the cellular basis of hyperexcitability and
synchronization in epilepsy and other neurological diseases.
The functional significance of transmitter release from
astrocytes involves modulation of the strength of excitatory
and inhibitory synaptic transmission by activating receptors
and neurons. As each astrocyte can reach thousands of
synapses simultaneously, the release of gliotransmitter may
lead to synchronization of neuronal firing patterns. Epilepsy
is often accompanied by massive glial cell proliferation,
even though the exact role of these cells in seizures and
epilepsy is still unclear. Not only do glial cells express
various ion channels and receptors, but they are probably
functionally heterogeneous. Therefore, a better understand-
ing of mechanisms of glial function in brain health and
disease may offer the potential for developing novel
strategies to treat epilepsy and other brain disorders. The
current anticonvulsant drugs and complementary therapies
are not sufficient to control seizures in about a third of
epileptic patients. Thus, there is an urgent need for
treatments that prevent the development of epilepsy and
control it better in patients already inflicted with the
disease. Despite significant advances in different fields of
neuroscience, the pathological mechanisms of epileptic
disorders remain poorly understood. An improved under-
standing of astrocyte biology and the involvement of glial
cells in epileptogenesis offers the potential for developing
novel strategies to treat epilepsy. Work in his laboratory had
recently identified two distinct types of cells with astroglial
properties, GluR cells and GluT cells, co-existing in mouse
hippocampus. GluR cells express ionotropic glutamate
receptors of the α-amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) subtype, receive synaptic input
from hippocampal neurons, and lack functional glutamate
transporters and gap junction coupling. GluT cells, in
contrast, display glutamate transporter activity, gap junction
coupling, touch brain capillaries with their endfeet, but lack
ionotropic glutamate receptors. Both types of astroglial
cells are also present in the hippocampus of patients
presenting with intractable temporal lobe epilepsy (lesion-
associated, non-sclerotic epilepsy). However, in patients
suffering from Ammon’s horn sclerosis, the most common
type of neuropathological damage seen in individuals with
temporal lobe epilepsy, one subpopulation of these cells
(GluT-type) almost completely disappears while the
remaining GluR cells undergo molecular and functional
alterations of their glutamate receptors. These findings
support the hypothesis that glial cells play a key role in the
generation and/or spread of seizure activity in human
epilepsy. This deleterious effect is brought about by (1)
the abundant excitatory neurotransmitter glutamate and (2)
impaired gap junction-mediated buffering of K
+ and
metabolites, leading to prolonged activation of cells in the
hippocampus, a brain region crucially involved in learning,
memory and emotional processing. Analyses of more than a
hundred brain specimens neurosurgically resected from
epilepsy patients were used to substantiate this intriguing
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epileptogenesis according to which neurons are considered
the prime targets affected in this disease.
Professor Francesco Di Virgilio, from the Department
of Experimental and Diagnostic Medicine, University of
Ferrara, Italy, presented the last talk of the morning
session entitled ‘Immuno-neural interaction and neuro-
inflammatory diseases’. He discussed the molecular
mechanisms underlying neuro-inflammation, in particular,
the two-way communication between neurons and micro-
glia, in which purinergic signalling (ATP and the ionotropic
ATP receptor subtype P2X7) constitutes a key pathway.
Release of ATP from neurons directly modulates microglial
function, resulting in secretion of neurotrophic factors, or, if
excessive or protracted, in the release of proinflammatory
mediators, amongst which interleukin (IL)-1β and IL-18
are the cytokines most tightly controlled by the P2X7
receptor. Conversely, purinergic stimulation of microglia
via P2 receptors may elicit microglial ATP release that
feeds back onto neurons. P2X7 receptor activation may lead
to inflammation by activation of the “inflammasome”,a
protein complex that activates inflammatory caspases.
Unique to the P2X7 receptor is that prolonged stimulation
leads to the opening of a large-conductance pore, which
corresponds to a gap junction-like hemichannel, the
pannexin, panx-1, that participates in the P2X7 receptor-
dependent inflammasome activation. This recent view on
P2X7 receptor-inflammasome interaction may open unan-
ticipated avenues for the development of novel anti-
inflammatory drugs.
Francesco pointed out that we are taught during
neurobiology courses that the brain is an immunologically
privileged organ; however, this does not mean that the brain
is devoid of immune cells and that immuno-mediated
reactions cannot occur in the brain. On the contrary, it is
becoming increasingly clear that resident immunocompe-
tent cells are crucial in the physiological homeostasis of the
central nervous system (CNS). Although it was long
thought that the brain was unable to mount an inflammatory
response, it is now clear that, with some relevant differ-
ences with respect to peripheral tissues, the CNS can
undergo all the typical changes of inflammation, can
activate endogenous inflammatory cells and generate
inflammatory mediators. Neurons are surrounded by a wide
population of support cells (oligodendroglia, astroglia and
microglia) that establish intimate physical relationships
with the neurons and exchange with them a wealth of
biochemical information. Among these cells, microglia
have a special status as these cells are both supportive and
immunocompetent. In this capacity, microglia share all the
positive and negative roles of their relatives located in the
periphery, i.e. tissue macrophages. In fact, although there
are no doubts that microglia have a key protective role in
CNS trauma or infections, or even during regeneration, it is
equally clear that microglia are a fundamental culprit in
CNS dysfunction.
Microglia release several factors that affect neuronal
functions: activated oxygen and nitrogen species, cytokines,
chemokines and growth factors. In turn, microglia are the
target of mediators released from neurons. We have only
very recently started to understand the subtleties of this
exchange of information and extracellular nucleotides have
been identified among the most relevant components of this
two-way traffic. Neurons are a rich source of ATP, which
has now an established role as a cotransmitter in most
major nerve types. Secretory exocytosis seems to be the
most common pathway for ATP release. Furthermore, other
cells such as astrocytes may also take part in this
communication network by releasing nucleotides or neuro-
transmitters that in turn evoke ATP release from neurons.
IL-1β is one of the most important proinflammatory
mediators, implicated in a variety of neurodegenerative
conditions. We now know that secretion of IL-1β is the end
result of a complex chain of tightly controlled intracellular
events occurring within a multimolecular structure named
the “inflammasome”. Dependence of IL-1β release on
extracellular ATP makes microglia an obvious target of
neuronal activity, especially in the presence of high levels
of neurotransmitter release. Under these conditions, if
microglia are also primed by exogenous or endogenous
proinflammatory factors, this may lead to sustained IL-1β
release and neuronal damage. There is scattered evidence
that this mechanism may play a role in the pathogenesis of
chronic CNS pathologies, notably Alzheimer’s disease.
The afternoon session was focused on purinergic
receptors in glia-neuron interactions. An overview of
‘Purinergic receptors and signalling mechanisms’ was
introduced by Professor Geoffrey Burnstock, President of
the Autonomic Neuroscience Centre, Royal Free and
University College Medical School, London, UK. He
reviewed how purinergic transmission was proposed in
the early 1970s, with evidence that ATP was a neurotrans-
mitter in non-adrenergic, non-cholinergic nerves in the gut
and urinary bladder. Later, it was shown to be a
cotransmitter with classic neurotransmitters and it is now
recognised as a cotransmitter in most, if not all, nerve types
in the peripheral and central nervous systems. Implicit in
purinergic neurotransmission is the existence of postjunc-
tional receptors for ATP. Released ATP is broken down by
ectonucleotidases to ADP, AMP and adenosine, and in
1978 separate receptors for adenosine and AMP (named P1
receptors) and for ATP and ADP (named P2 receptors) were
proposed. In the early 1990s, P1 and P2 receptors were
cloned and characterised: four P1 receptor subtypes (A1,
A2A,A 2B and A3), seven subtypes of P2X ligand-gated ion
channel receptors (P2X1-7) and eight subtypes of P2Y
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P2Y2, 4, 6 receptors are activated by the pyrimidines uridine
triphosphate (UTP) or uridine diphosphate (UDP) as well as
by purine nucleotides. The cation channel is formed by
three P2X receptor subunits either forming homomultimers
or heteromultimers. P2X1/2, P2X2/3, P2X1/4, P2X1/5, P2X2/6,
P2X4/6 and probably P2X4/7 heteromultimer receptors are
widely expressed in vivo and have different pharmacolog-
ical properties from homomultimers. Reverse transcription
polymerase chain reaction (RT-PCR) and immunohisto-
chemical studies have shown widespread expression of P1
and P2 receptor mRNA and protein in neuronal and non-
neuronal tissues. Both short-term purinergic signalling in
neurotransmission, secretion and platelet aggregation and
long-term (trophic) purinergic signalling in cell prolifera-
tion, migration, differentiation and death in development
and regeneration have been recognised.
Formany years itwasassumedthat thesource of ATPwas
dying cells, but it is now recognised that many cells release
ATP physiologically in response to mechanical stimuli and
hypoxia, although the mechanism of ATP transport is still
debated. ATP release from nerves and some other cells is
vesicular; from others it may involve ABC transporters,
connexin or pannexin hemichannels or P2X7 receptor pores.
Expression of purinergic cotransmitters and receptors
shows plasticity in development and old age, in the nerves
that remain after trauma or surgery and in disease.
For many years, it was recognised that adenosine, acting
through P1 (usually A1) presynaptic receptors to inhibit the
release of excitatory transmitters, was an important mecha-
nism in the CNS. However, in 1992, evidence was presented
for ATP mediating synaptic neurotransmission in the medial
habenula and since then there has been an explosion of
interest in purinergic neurotransmission and neuromodula-
tion in the different regions of the brain and spinal cord.
Multiple purinergic receptors have also been identified on
astrocytes, oligodendrocytes and microglia and important
mechanisms involving neuron-glial cell interactions have
been recognised, as reviewed recently [1]. There is increas-
ing interest in the role of purinergic signalling in the
pathophysiology of neurological disorders, including: trau-
ma, stroke and ischaemia; neurodegenerative diseases such
as Alzheimer’s, Parkinson’s and Huntington’s, multiple
sclerosis and amyotrophic lateral sclerosis; migraine;
neuro-psychiatric disorders such as schizophrenia, anxiety
and depression; epileptic seizures; and neuropathic pain.
Purinergic therapeutic strategies for the treatment of these
conditions are beginning to be explored.
Professor Herbert Zimmermann, from the Institute of
Cell Biology and Neuroscience Biocenter, University of
Frankfurt, Germany, gave the next talk entitled ‘Regulation
of purinergic signalling by ectonucleotidases’. He de-
scribed how extracellular nucleotides are hydrolyzed by
plasma membrane-located enzymes with an extracellulary
oriented catalytic site (ectonucleotidases). Ectonucleo-
tidases modulate ligand availability at nucleotide and
nucleoside receptors. Apart from that, they serve the
recycling of nucleosides via specific cellular transport
systems. Substrates of ectonucleotidases include nucleoside
triphosphates, diphosphates and monophosphates and dinu-
cleoside polyphosphates. The final hydrolysis products are
phosphate or pyrophosphate and the nucleoside whereby
several enzyme species can be involved in completing the
hydrolysis chain. Ectonucleotidases are molecularly even
more diverse than P2 receptors and include several enzyme
families. Amongst these are the ectonucleoside triphosphate
diphosphohydrolase family (E-NTPDases), the ectonucleo-
tide pyrophosphatase/phosphodiesterase family (E-
NPPases), the alkaline phosphatases, ecto-5′-nucleotidase
and a variety of enzymes involved in the extracellular
interconversion of nucleotides such as ectonucleoside
diphosphokinase and ecto-ATP:AMP phosphotransferase
(adenylate kinase, myokinase). To date, most of the
ectonucleotidases have been identified and characterised
in molecular and functional terms. The enzymes are equally
abundant as nucleotide receptors and reveal a wide and
partially overlapping tissue distribution.
The diversity of the individual family members is consid-
erable and it is still difficult to assign the modulation of
purinergic signalling pathways to identified enzymes. In the
brain, members of all ectonucleotidase families are expressed.
Physiological implications include the modulation of synaptic
transmission, the ATP-mediated propagation of glial Ca
2+
waves, microglial function, adult neurogenesis and the
control of vascular tone, haemostasis and thromboregulation.
Research on ectonucleotidases now continues in diverging
directions, addressing e.g. structure-function relationships,
overexpression and knockdown, crystallization and atomic
structure analysis and physiological analysis. Yet, consider-
ably more detailed information concerning tissue and cellular
localisation of the individual ectonucleotidases is required for
understanding their potential interaction with extracellular
nucleotide signalling pathways. To date, NTPDase1, NPP1,
ecto-5′-nucleotidase and two isoforms of alkaline phosphatase
have been deleted in mice. As yet, no inducible knockouts are
available. The development of additional knockout models
will be of great importance to further define the physiological
significance of the individual enzyme isoforms. This needs to
be flanked by the development of inhibitors that do not
affect nucleotide receptors and target individual enzyme
isoforms. Together these studies will provide both an
understanding of the molecular structure and of the physio-
logical function of ectonucleotidases at a considerably higher
level of resolution.
Professor Peter Illes, Chairman of the Department of
Pharmacology, University of Leipzig, Germany, gave the
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protection and nerve growth’. He described how noxious
stimuli lead to the outflow of ATP via the damaged cell
membrane and subsequently may activate a certain subtype
of ionotropic P2X receptor (P2X3), or metabotropic P2Y
receptor (P2Y1), both situated at the nociceptive C fibre
terminals. These fibres originate from sensory neurons
located in nodose or dorsal root ganglia (DRG). P2X3
receptors are algogenic by mediating depolarization, prop-
agated action potentials and, in consequence, glutamate
release from the central terminals of small-diameter sensory
neurons in the dorsal horn of the spinal cord. In contrast,
P2Y1 receptors cause opposite effects through the blockade
of voltage-sensitive Ca
2+ channels, which normally initiate
transmitter release. In addition, a negative interaction
between P2Yand P2X receptors was described via G protein
involvement in the cell bodies of DRG neurons. Moreover,
various nucleotides, including ATP, have been suggested to
phosphorylate, by means of ecto-protein kinases, the
extracellular loop of P2X3 receptors and thereby to increase
the conductance of these receptor channels. Eventually,
long-lasting contact with subthreshold concentrations of
ATP is sufficient to induce a massive desensitization of the
P2X3 receptor. Hence, P2X3 and P2Y1 receptors alone or in
concert shape the strength and duration of painful stimuli at
the level of the peripheral nervous system.
In the CNS, both neuronal damage and mechanical
distortion may rapidly increase the extracellular concentra-
tion of nucleotides. In particular, the effects of stab wound
injury and hypoxia/ischaemia have been extensively inves-
tigated. ATP can either aggravate or ameliorate the extent
and intensity of the original damage. An aggravation could
be due to the activation of P2X7 receptors, which have a low
sensitivity to ATP, but may open large holes in the plasma
membrane of astrocytes, microglia, or even neurons,
initiating apoptotic or necrotic processes. All P2X receptor
subtypes may lead, because of their Ca
2+ permeability, to
an overload of cells by Ca
2+ and thereby to apoptosis. On
the other hand, astrocytic P2Y1 receptors may mediate
proliferation and the production of glial scars interfering
with the re-establishment of normal axonal connections. In
the nucleus accumbens, P2X1 and P2X7 receptors were
absent on astrocytes of untreated rats, but became expressed
after mechanical damage. Similarly, P2Y2 and P2Y6
receptors appeared only after stab wound injury on the
accumbal astrocytes. Several P2 receptor subtypes were up-
regulated by the introduction of an injection cannula into
the nucleus accumbens and still more so by the application
of the mixed P2X/P2Y receptor agonist 2-methylthio ATP
(2-MeSATP) or the P2Y1, 12, 13 selective agonist ADP-β-S.
The co-application of selective antagonists [pyridoxal-
phosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS),
MRS2179] confirmed the preferential involvement of the
P2Y1, 12, 13 receptors with a minor contribution of P2X
receptor subtypes. The intracerebroventricular application
of PPADS alleviated the morphological and functional
consequences of ischaemia in an in vivo stroke model (rat
medial cerebral artery occlusion) confirming the patho-
physiological role of ATP.
Extracellular ATP may promote nerve growth alone or in
conjunction with various growth factors. In co-cultures of the
entorhinal cortex and the hippocampus, fibre growth was
visualized by the anterograde tracer biocytin, which was
placed onto the entorhinal part of the co-culture. The
entorhinal fibre outgrowth was increased by 2-MeSATP in
the absence but not in the presence of PPADS. Hence, some
unidentified P2 receptors may exert a trophic influence under
these conditions. A similar effect was observed when the
ventral tegmental area/substantia nigra complex was co-
culturedwiththeprefrontalcortex.Inconclusion,extracellular
ATP, through the activation of various P2 receptor subtypes
may modulate pain, neuronal damage and nerve growth.
Professor Maria Abbracchio, Department of Pharma-
cological Science, University of Milan, Italy, gave the final
talk, entitled ‘Agonists and antagonists of old and new P2
receptors’. Extracellular purine and pyrimidine nucleotides
areubiquitoussignallingmoleculesthatmodulatethefunction
of diverse mammalian cell types and tissues under both
physiologicalandpathologicalconditions.Thehighlyspecific
actions of these neurotransmitters are mediated by the
activation of two distinct families of membrane receptors:
the P2Xreceptorchannelsandthe P2Yreceptors belongingto
the G protein-coupled seven-transmembrane (7-TM) receptor
(GPCRs) superfamily. Seven distinct P2X receptor subunits
(P2X1-P2X7) forming multimeric ligand-gated sodium and
calcium channels have been identified; conversely, eight
subtypes of P2Y receptors (P2Y1, 2, 4, 6, 11, 12, 13, 14
receptors) are officially recognised by the IUPHAR (Inter-
national Union of Pharmacology) Subcommittee for P2Y
Receptor Nomenclature and Classification. Several non-
selective agonists (e.g. hydrolysis-resistant adenine and
uracil nucleotide analogs) and antagonists (e.g. suramin,
Reactive Blue 2, Brilliant Blue G) have been available
during the years, but it has been only recently that ligands
displaying selectivity towards specific P2 receptor subtypes
have been made available. Besides being important pharma-
cological tools for the characterization of the pathophysio-
logical roles of P2X and P2Y receptors in native systems,
there is agreement that such ligands may represent new
therapeutic entities of potential interest in a variety of human
diseases, including pain, depression, stroke and chronic
neurodegenerative disorders. The design and synthesis of
selective P2Y ligands has been greatly aided by the
development of three-dimensional structures of these recep-
tors via structure-activity relationships, mutagenesis and
homology modelling studies based on the crystallization of
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of P2X receptors have not been proposed yet, due to the
lack of a suitable protein template. Recent work has
identified nucleotide agonists selective for P2Y1,P 2 Y 2 and
P2Y6 receptors and nucleotide antagonists selective for
P2Y1 (MRS2179, MRS2500), P2Y12/13 (Congrelor, previ-
ously known as AR-C69931MX) and P2X1 receptors.
Selective non-nucleotide antagonists have been reported for
P2Y1, 2, 6, 12, 13 and P2X2/3/P2X3 and P2X7 receptors. For
example, the dinucleotide INS37217 (UP4dC) potently
activates the P2Y2 receptor and the non-nucleotide antago-
nist A-317491 is selective for P2X2/3/P2X3 receptors.
Dr. Abbracchio described a recently reported “deorpha-
nization” of a new P2Y receptor, formerly known as the
“orphan” GPR17 receptor. Phylogenetically and structurally,
GPR17 is closely related to both the P2Y12, 13, 14 subfamily
of P2Y receptors and to CysLT1 and CysLT2 receptors.
Hence, its ligand specificity could not be predicted simply
based on its phylogenetic position. It was shown that this
receptor responded dually to both uracil nucleotides and
cysteinyl-leukotrienes, a family of proinflammatory arach-
idonic acid metabolites. Activation of GPR17 by uracil
nucleotides can be counteracted by P2Y receptor antago-
nists such as MRS2179 or cangrelor, whereas its activation
by CysLTs can be blocked by already known CysLT
antagonists, such as Montelukast and Prankulast. Since
both extracellular nucleotides and CysLTs are released in
great amounts in ischaemic brain, it was hypothesized that
the pathological activation of GPR17 by these endogenous
ligands may contribute to ischaemia-associated neuronal
death. In line with this hypothesis, the in vivo knockdown
of GPR17 by either P2Y/CysLT antagonists or by an
anti-sense oligonucleotide strategy markedly prevented
ischaemia evolution. GPR17 thus represents the first fully
characterised example of a dual GPCR responding to two
distinct unrelated classes of non-peptide endogenous
ligands. However, the P2Y12 receptor has been also
reported to respond to the cysteinyl-leukotriene LTE4,
suggesting that there may exist several GPCRs character-
ised by a dual pharmacology, and, in particular, that the
P2Y12, 13, 14 subfamily of P2Y receptors may interact with
both nucleotides and CysLT with high affinity. The
existence of dual receptors opens the possibility of
developing dual ligands characterised by previously unex-
plored therapeutic potency. In particular, it was envisaged
that dual GPR17 antagonists may represent a novel class of
potent anti-neurodegenerative agents.
The formal presentations were followed by a discussion
session with lively exchanges of views between the speakers
and members of UCB staff. Some promising therapeutic
targets were identified. Marc De Ryck thanked the speakers
for their authoritative and informative presentations and said
that UCB would now consider the way forward.
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